Friend says that he is cognizant of the fact that he's trailing Pfizer, and that he is investing in IGF-1 only because he thinks Merck can develop a market for the drug by having a better scientific understanding of how the drug works--and testing it in populations, and as part of drug combinations, where it will be most effective.
FORBES: Cancer Revolution, Or Me-Too Mess?